Baird analyst Jack Allen lowered the firm’s price target on Intellia Therapeutics (NTLA) to $18 from $24 and keeps a Neutral rating on the shares. The firm said they incrementaly negaitve following the Phase 2 study of NTLA-2002 in patients with hereditary angiodema (HAE).
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Cathie Wood’s ARK Investment buys 216.2K shares of Intellia Therapeutics today
- Intellia Therapeutics price target lowered to $88 from $94 at Chardan
- Boeing union rejects latest offer, Tesla reports Q3 beat: Morning Buzz
- Intellia Therapeutics presents results from Phase 2 study of NTLA-2002
- Cathie Wood’s ARK Investment bought 162K shares of Intellia Therapeutics today